Glenmede Trust Co. NA Has $109.84 Million Stock Position in Abbott Laboratories $ABT

Glenmede Trust Co. NA lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.7% during the first quarter, HoldingsChannel reports. The fund owned 1,069,850 shares of the healthcare product maker’s stock after selling 65,035 shares during the quarter. Glenmede Trust Co. NA’s holdings in Abbott Laboratories were worth $109,841,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of ABT. Vanguard Group Inc. increased its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. State Street Corp lifted its stake in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after buying an additional 1,627,791 shares during the period. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after buying an additional 1,614,706 shares during the period. J. Stern & Co. LLP grew its position in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its stake in Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after acquiring an additional 400,400 shares during the period. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the company. Leerink Partners reduced their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. TD Cowen restated a “buy” rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Jefferies Financial Group decreased their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Barclays lowered their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $105.99 on Friday. The firm has a market capitalization of $183.40 billion, a P/E ratio of 34.30, a P/E/G ratio of 2.04 and a beta of 0.61. The stock has a fifty day moving average price of $93.45 and a two-hundred day moving average price of $100.62. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Raised earnings estimate: Erste Group Bank increased its FY2026 EPS forecast for Abbott to $5.52 from $5.47, matching the broader consensus estimate. The revision reinforces expectations for continued earnings growth. Erste Group raises Abbott earnings estimate
• Positive Sentiment: Recent results remain supportive: Abbott’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 13% year over year. Management also provided FY2026 EPS guidance of $5.45 to $5.60, supporting the positive earnings narrative.
• Positive Sentiment: Strategic diversification and income appeal: A comparison with Johnson & Johnson highlighted Abbott’s broad exposure to medical devices and diagnostics, strengthened by the Exact Sciences acquisition. Separately, analysts continue to identify ABT as an attractive Dividend Aristocrat for investors seeking recurring cash income. Abbott versus Johnson and Johnson comparison
• Neutral Sentiment: Healthcare-sector momentum: Strong performances from AbbVie and Guardant Health indicate continued investor interest in healthcare and diagnostics, but these companies’ results do not directly change Abbott’s fundamentals.
• Negative Sentiment: Valuation pressure: UBS lowered its expectations for Abbott’s stock price, potentially limiting upside and weighing on sentiment after the recent recovery. UBS lowers Abbott stock price expectations

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.